Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.

Pathology, research and practice - 1 Aug 2020

Sun Lei, Wang Run-Chang, Zhang Qing, Guo Lin-Lang

Abstract excerpt

The morbidity and mortality of endometrial cancer has been increasing over years. Ataxia telangiectasia mutated (ATM) gene, encoding a protein kinase participated in the response to DNA damage, is frequently mutated in endometrial cancer patients. However, the potential relationship between ATM mutations and the progression of endometrial cancer remains unclear. We performed an integrative bioinformatics analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Endometrial Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Lymphocytes, Tumor-Infiltrating

Share to Prognosis

Share to Tumor Microenvironment

Source

Identifiers

PMID: 32703496
DOI: 10.1016/j.prp.2020.153032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.PMID 32703496Read ↗

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.Semantic proximity Read ↗

Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironmentSemantic proximity Read ↗

Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.Semantic proximity Read ↗

Establishing a Prognostic Signature Based on Epithelial–Mesenchymal Transition-Related Genes for Endometrial Cancer PatientsSemantic proximity Read ↗

Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection.Semantic proximity Read ↗

Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target TherapySemantic proximity Read ↗

Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative treatmentsSemantic proximity Read ↗

Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment.Semantic proximity Read ↗

Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancerSemantic proximity Read ↗

Bioinformatic Profiling Identifies Prognosis-Related Genes in the Immune Microenvironment of Endometrial CarcinomaSemantic proximity Read ↗

Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.Semantic proximity Read ↗

Significance of Tumor Infiltrating Immune Cells (TIICs) in Endometrial carcinoma: A Bioinformatics AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.